News · 26 weeks400%
2026-04-192026-10-11
Mix1890d
- Other6(33%)
- SEC Filings5(28%)
- Insider4(22%)
- Leadership3(17%)
Latest news
25 items- PRSCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)• SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated • Phase 2 proof-of-concept study in patients with ADPKD remains on-track to initiate in the fourth quarter of 2026 • SCY-770 is a potential first-in-class oral direct AMPK activator designed to address multiple underlying drivers of cyst growth and disease progression in ADPKD JERSEY CITY, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced completion of a Phase 1 study of SCY-770, a first-in-class, selective and direct AMP-act
- SECSCYNEXIS Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure8-K - SCYNEXIS INC (0001178253) (Filer)
- PRSCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247BARDA partnership accelerates development of SCY-247 as a potential therapy for the treatment and prevention of serious invasive fungal infections, addressing a critical public health needNon-dilutive funding for SCY-247 enables advancement of a Phase-2 ready program, strengthening the pipeline, enhancing portfolio optionality, and bolstering the Company’s long-term value propositionThe Company does not anticipate any changes to its previously communicated guidance regarding development milestones for SCY-770, its lead product candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD), or the Company’s cash runway into 2029 JERSEY CITY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- SCY
- INSIDERDirector Burke Steven Keith was granted 5,750 shares (SEC Form 4)4 - SCYNEXIS INC (0001178253) (Issuer)
- INSIDERSEC Form 3 filed by new insider Burke Steven Keith3 - SCYNEXIS INC (0001178253) (Issuer)
- SECSCYNEXIS Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure8-K - SCYNEXIS INC (0001178253) (Filer)
- PRSCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of DirectorsJERSEY CITY, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX) ("SCYNEXIS" or the "Company"), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Steven K. Burke, M.D., to its Board of Directors, effective September 18, 2026. Dr. Burke brings more than 30 years of industry experience, with a particular focus on drug development for chronic kidney disease. He has worked at Akebia Therapeutics, Inc. since 2019, and has served as its Senior Vice President, Chief Research and Development Officer and Chief Medical Officer since 2021. Dr. Burke has responsibility for Akebia’s research
- PRSCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & DevelopmentJERSEY CITY, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Todd Minga, M.D. as Senior Vice President, Research & Development, effective September 14, 2026. Dr. Minga brings more than two decades of experience spanning clinical medicine, drug development, medical affairs, clinical research, and strategic leadership in kidney disease and rare disorders. He joins SCYNEXIS from Akebia Therapeutics, where he most recently served as Vice President, Medical Affairs and Clinical Development. In that role,
- INSIDERSEC Form 4 filed by Chief Financial Officer Subramanian Sanjay4 - SCYNEXIS INC (0001178253) (Issuer)
- INSIDERSEC Form 3 filed by new insider Subramanian Sanjay3 - SCYNEXIS INC (0001178253) (Issuer)
- SECSCYNEXIS Inc. filed SEC Form 8-K: Leadership Update, Other Events8-K - SCYNEXIS INC (0001178253) (Filer)
- PRSCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial OfficerJERSEY CITY, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Sanjay Subramanian, MBA, as Chief Financial Officer, effective September 9, 2026. The Company also announced the retirement of Ivor Macleod from his role as Chief Financial Officer, effective September 9, 2026. Mr. Macleod will remain with the Company through October 9, 2026 to support a smooth transition. "We are delighted to welcome Sanjay to SCYNEXIS and excited to add his extensive financial and strategic leadership experience to our e
- PRSCYNEXIS to Participate in Upcoming Investor ConferencesJERSEY CITY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced that the company will participate in the following investor conferences: 12th Cantor Global Healthcare Conference in New York City Fireside chat: Friday, September 11, 2026, at 9:45 a.m. ET. H.C. Wainwright 28th Annual Global Investment Conference in New York City 1x1 investor meetings: September 14-16, 2026 A live webcast of the Cantor fireside chat will be available here. A replay will be available for 90 days following the eve
- PRSCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)JERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced the grant of an inducement equity award to a new Senior Director, with a grant date of August 24, 2026. The award was granted in connection with the commencement of the Senior Director’s employment with the Company, as a material inducement to the employee’s acceptance of employment, and was approved in accordance with Nasdaq Listing Rule 5635(c)(4). The award was granted pursuant to SCYNEXIS’ 2015 Inducement Award Plan, as amended,
- PRSCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateInitiated a Phase 1 study of SCY-770, a first-in-class, potent and direct AMPK activator for treatment of ADPKD; topline data are expected in Q3 2026 and are anticipated to inform dose selection for the planned Phase 2 study The Phase 2 proof-of-concept study of SCY-770 in patients with ADPKD remains on track for initiation in Q4 2026, with an early efficacy read-out expected in the second half of 2027Completed dosing in the Phase 1 study of the IV formulation of second-generation antifungal SCY-247, with topline data on track for Q3 2026Ended Q2 2026 with cash, cash equivalents and investments of $71.1 million, supporting a cash runway into 2029 JERSEY CITY, N.J., Aug. 10, 2026 (GLOBE N
- SECSEC Form S-8 filed by SCYNEXIS Inc.S-8 - SCYNEXIS INC (0001178253) (Filer)
- SECSEC Form 10-Q filed by SCYNEXIS Inc.10-Q - SCYNEXIS INC (0001178253) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SCYNEXIS Inc.SCHEDULE 13G/A - SCYNEXIS INC (0001178253) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SCYNEXIS Inc.SCHEDULE 13G/A - SCYNEXIS INC (0001178253) (Subject)
- INSIDERDirector Tinmouth Brian Philippe was granted 2,875 shares, increasing direct ownership by 31% to 12,125 units (SEC Form 4)4 - SCYNEXIS INC (0001178253) (Issuer)
- INSIDERDirector Macdonald Guy was granted 2,875 shares, increasing direct ownership by 29% to 12,625 units (SEC Form 4)4 - SCYNEXIS INC (0001178253) (Issuer)
- INSIDERDirector Anido Armando was granted 2,875 shares, increasing direct ownership by 32% to 11,750 units (SEC Form 4)4 - SCYNEXIS INC (0001178253) (Issuer)
- INSIDERDirector Hastings David C was granted 2,875 shares, increasing direct ownership by 33% to 11,522 units (SEC Form 4)4 - SCYNEXIS INC (0001178253) (Issuer)
- INSIDERDirector Hanham Ann was granted 2,875 shares, increasing direct ownership by 33% to 11,577 units (SEC Form 4)4 - SCYNEXIS INC (0001178253) (Issuer)
- PRSCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced initiation of a Phase 1 study of SCY-770, a first-in-class, potent and direct AMP-activated protein kinase (AMPK) activator. The study will characterize the food-effect and define the pharmacokinetics of two dosing regimens for SCY-770 to support dose selection for the Phase 2 study in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD), on track for Q4 2026. "Initiating this Phase 1 study of SCY-770 marks an important milestone for SCYNEXIS as we advance a highly differentiated therapy
SCYX FAQ
6 questionsWhat does SCYNEXIS Inc. do?
SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai)...Where does SCYX stock trade?
SCYNEXIS Inc. (SCYX) is listed on NASDAQ.What sector and industry is SCYX in?
SCYNEXIS Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did SCYNEXIS Inc. go public?
SCYNEXIS Inc. (SCYX) completed its IPO in 2014.What companies are similar to SCYX?
Notable peers in the same industry include INTT (inTest Corporation), CDTX (Cidara Therapeutics Inc.), NBSE (NeuBase Therapeutics Inc.), SACH (Sachem Capital Corp.). Compare SCYX side-by-side with any of them on Quantisnow.How can I track SCYX on Quantisnow?
Quantisnow aggregates SCYNEXIS Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SCYX to receive live email and push alerts on every new disclosure.